Pfizer: Positive Preliminary Phase 2 Results for 20-Valent Vaccine Candidate in Infants
September 09 2019 - 9:11AM
Dow Jones News
By Colin Kellaher
Pfizer Inc. (PFE) on Monday reported positive preliminary
results from a phase 2 proof-of-concept study of its 20-valent
pneumococcal conjugate vaccine candidate in infants.
The New York drug maker said the initial three doses in the
four-dose study showed preliminary evidence that the vaccine
candidate in infants has an overall safety profile similar to
Pfizer's Prevnar 13 vaccine.
Pfizer said the findings should support the program's
advancement to phase 3 studies, adding that it will discuss phase 3
plans with regulators once data with the fourth dose are
available.
Pfizer said the study is assessing the safety and immunogenicity
of the 20vPnC candidate for the prevention of invasive disease and
otitis media caused by Streptococcus pneumoniae serotypes contained
in the vaccine in healthy infants.
The 20vPnC candidate includes the 13 serotypes contained in
Prevnar 13, plus seven additional Streptococcus pneumoniae
serotypes that represent prevalent circulating global disease
strains, the company said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 09, 2019 08:56 ET (12:56 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Sep 2023 to Sep 2024